

AmSustainable Series - Positive Change Fund

Fund Overview

Investment Objective

AmSustainable Series - Positive Change Fund (the "Fund") seeks to provide long-term capital growth.

The Fund is suitable for sophisticated investors seeking:


- · potential capital appreciation over a long-term investment horizon; and
- · participation in the global equity market.

Note: *Long term refers to a period at least five (5) years.

Any material change to the investment objective of the Fund would require Unit Holders' approval

Fund Performance (as at 30 April 2025)

Cumulative performance over the period (%)



Past performance is not necessarily indicative of future performance. Unit prices and investment returns may go down as well as up Source: AmFunds Management Berhad

Performance Table in Share Class Currency (%) (as at 30 April 2025)

Cumulative Return (%)	YTD	1 Month	6 Months	1 Year	3 Years	5 Years
Fund (USD)	-0.24	1.24	-0.36	6.07	6.36	-
*Benchmark (USD)	-0.93	0.77	0.15	10.17	27.52	-
Fund (MYR-Hedged)	-1.23	0.78	-1.79	2.77	-3.74	-
Annualised Return (%)	3 Years	5 Years	10 Years	Since Inception	ı	
Fund (USD)	2.08	-	-	-5.71		
*Benchmark (USD)	8.43	-	-	4.21		
Fund (MYR-Hedged)	-1.26	-	-	-8.02		
Calendar Year Return (%)	2024	2023	2022	2021	2020	
Fund (USD)	2.04	13.51	-29.92	-	-	-
*Benchmark (USD)	15.73	20.09	-19.80	-	-	
Fund (MYR-Hedged)	-1.37	9.14	-31.13	-	-	

Source Fund Return: Novagni Analytics and Advisory Sdn. Bhd.
Past performance is not necessarily indicative of future performance. The performance is calculated based on NAV-to-NAV using Time Weighted Rate of Return ("TWRR")

Note: There is no record of the Fund's performance for five (5) years as the Fund was launched in less than five (5) years.

Fund Facts

Fund Category / Type

Wholesale (Feeder Fund) / Growth

Base Currency

USD

Investment Manager

AmFunds Management Berhad

Launch Date

USD Class 27 May 2021 MYR-Hedged Class 27 May 2021

Initial Offer Price

USD Class USD 1.0000 MYR-Hedged Class MYR 1.0000 Minimum Initial / Additional Investment

USD 1,000 / USD 1,000 **USD Class** MYR-Hedged Class MYR 5,000 / MYR 1,000

Annual Management Fee

Up to 1.80% p.a. of the Fund's NAV

Annual Trustee Fee

Up to 0.05% p.a. of the NAV of the Fund (excluding foreign sub-custodian fee and charges, where applicable)

Up to 5.00% of the NAV per unit of the Class(es)

Exit Fee

Nil

Redemption Payment Period

Within 14 calendar days of receiving the redemption request with complete documentation.

Income Distribution

MYR-Hedged Class

Distribution, if any, can be in the form of cash (by telegraphic transfer) or units (by reinvestment into units of the respective Classes).

Note: If income distribution earned does not exceed MYR 500, it will be automatically reinvested.

Other Classes

Distribution, if any, to be reinvested into units of the respective Classes

*Data as at (as at 30 April 2025)

NAV Per Unit

USD Class	USD 0.7938
MYR-Hedged Class	MYR 0.7203
Fund Size*	
USD Class	USD 0.38 million
MYR-Hedged Class	MYR 22.05 million
Unit in Circulation*	
USD Class	0.47 million
MYR-Hedged Class	30.61 million
1- Year NAV High*	
USD Class	USD 0.8537 (19 Feb 2025)
MYR-Hedged Class	MYR 0.7804 (19 Feb 2025)
1- Year NAV Low*	
USD Class	USD 0.6819 (07 Apr 2025)
MYR-Hedged Class	MYR 0.6205 (07 Apr 2025)

Source: AmFunds Management Berhad The above fees and charges may be subject to any applicable taxes and/or duties (imposed by the Government of Malaysia which are payable by the unit holder(s) and/or the Fund (as the case may be) at the prevailing rate.

8.00%


5.90%

5.30%

4.70%

4 70%

Asset Allocation (as at 30 April 2025)					
Baillie Gifford Worldwide Positive Change Fund Money market deposits and cash equivalents	9.70%	88.89%			
Forward contract	1.41%				
Source: AmFunds Management Berhad					



Target Fund's Sector Allocation* (as at 30 April 2025)						
Information Technology			23.00%			
Financials		17.00%				
Industrials		16.10%				
Consumer Discretionary		16.10%				
Health Care		14.70%				
Materials	6.90%					
Communication Services	5.60%					
Cash	■ 0.60%					
: Baillie Gifford & Co						

Target Fund's Country Allocation* (as at 30 April 2025)

Target Fund's Top 5 Holdings (as at 30 April 2025)


MercadoLibre **TSMC**

Duolingo

HDFC Bank

Source: Baillie Gifford & Co

ASML



*As percentage of NAV. Please note that asset exposure for the Target Fund is subject to frequent change on a daily basis.

Target Fund Manager's Commentary (as at 30 April 2025)

The first quarter of 2025 presented a challenging landscape for global equity markets, marked by persistent economic uncertainties and geopolitical tensions. Inflationary pressures, though easing, continued to influence monetary policies worldwide. The ongoing deglobalisation trend and shifting trade dynamics added complexity to the investment environment. Amidst this turbulence, the Positive Change Fund delivered negative returns. We maintain our conviction in the Target Fund's positioning to address critical global challenges that transcend short-term market fluctuations. The companies in the Target Fund are at the forefront of transformative solutions in areas such as healthcare, financial inclusion, and environmental sustainability – themes we believe will drive long-term value creation and positive societal impact.

MercadoLibre, Alnylam and SEA Ltd were the top contributors to performance. MercadoLibre is the leading ecommerce and fintech company in Latin America. The company's robust performance reflects its strong market position and continued growth in key segments. Its fintech arm, Mercado Pago, has shown impressive user acquisition and engagement metrics, while its core ecommerce business continues to benefit from increasing penetration rates across the region.

Alnylam's share price growth was driven by the FDA approval of its cardiovascular drug Amvuttra. This development underscores Alnylam's leadership in RNA interference therapeutics, a revolutionary approach to treating genetic disorders. The company's pipeline continues to show promise, with potential applications across a range of diseases.

Sea Limited showed strong growth across its three core business segments. Shopee, Sea's e-commerce platform, achieved 28% GMV growth while improving profitability in both Asian and Brazilian markets. Its digital financial services division also showed exceptional strength, with its loan book expanding over 60% year-on-year. Looking ahead, SEA is well-positioned to continue outperforming due to its expanding user base, increasing monetisation opportunities, and potential for further market penetration in both ecommerce and financial services across Southeast Asia's rapidly digitalising economies.

Among the biggest detractors from performance during the quarter were Illumina, TSMC and Moderna.

Illumina, a leader in DNA sequencing technology, faced challenges this quarter due to regulatory headwinds and slower-than-expected adoption of its high-throughput sequencing systems. Despite these short-term setbacks, we maintain our conviction in Illumina's long-term potential. The company's technologies are fundamental to advancing personalised medicine and genetic research, areas we believe will drive significant healthcare improvements in the coming decades.

TSMC, the world's largest semiconductor foundry, saw its performance detract due to concerns over global chip demand and geopolitical tensions. However, we believe TSMC's technological leadership and crucial role in the global semiconductor supply chain position it well for long-term growth. Furthermore, the company's commitment to advancing chip manufacturing technology and the increasing importance of semiconductors make it one of the key enablers of various technological advancements.

Moderna experienced a challenging financial year, with revenues significantly lower than the previous year. The decline in COVID-19 vaccine sales and the RSV vaccine's struggles against established competitors, combined with recent FDA leadership changes, have further unsettled investor confidence. With its validated mRNA platform demonstrating a significantly higher success rate than traditional drug development approaches, we believe Moderna is well-positioned to create long-term value through its technological advantages in multiple therapeutic areas.

Source: Baillie Gifford & Co

Disclaimer

Source: MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com).

This advertisement material is prepared for information purposes only and may not be published, circulated, reproduced or distributed in whole or part, whether directly or indirectly, to any person without the prior written consent of AmFunds Management Berhad [198601005272 (154432-A)] ("AmInvest"). This advertisement material should not be construed as an offer or solicitation for the purchase or sale of any units in AmInvest's wholesale fund(s). Investors shall be solely responsible for using and relying on any contents in this advertisement material. AmInvest and its employees shall not be held liable to the investors for any damage, direct, indirect or consequential losses (including loss of profit), claims, actions, demands, liabilities suffered by the investors or proceedings and judgments brought or established against the investors, and costs, charges and expenses incurred by the investors or for any investment decision that the investors have made as a result of relying on the content or information in this advertisement material. Investors are advised to read and understand the contents of the Replacement Information Memorandum dated 24 December 2021 for Sustainable Series - Positive Change Fund, including any supplementary made thereof from time to time ("Information Memorandum(s)") and its Product Highlights Sheet ("PHS"), obtainable at www.aminvest.com, before making an investment decision. The Information Memorandum(s) and PHS have been lodged with the Securities Commission Malaysia, who takes no responsibility for its contents. The Securities Commission Malaysia has not reviewed this advertisement material. Investors may wish to seek advice from a professional advisor before making an investment. The Fund's units will only be issued upon receipt of the complete application form accompanying the Information Memorandum(s). Past performance of the Fund is not an indication of its future performance. The Fund's unit prices and income distribution payable, if any, may rise or fall. Where a unit split/distribution is declared, investors are advised that following the issue of additional units/distribution, the Net Asset Value ("NAV") per unit will be reduced from pre-unit split NAV/cum-distribution NAV to post-unit split NAV/ex-distribution NAV. Please be advised that where a unit split is declared, the value of investor's investment in Malaysian Ringgit will remain unchanged after the distribution of the additional units. Investments in the Fund are exposed to risk of passive strategy, risk of not meeting the Fund's investment objective, currency risk, income distribution risk and liquidity risk. Please refer to the Information Memorandum(s) for detailed information on the specific risks of the fund(s). Investors are advised to consider these risks and other general risk elaborated, as well as the fees, charges and expenses involved. This advertisement material may be translated into languages other than English. In the event of any dispute or ambiguity arising out of such translated versions of this advertisement material, the English version shall prevail. AmInvest's Privacy Notice can be accessed via aminvest.com.Note: Unless stated otherwise, all fees, charges and/or expenses disclosed in this material are exclusive by way of example and not limitation; goods and services tax, value added tax, consumption tax, levies, duties and other taxes as may be imposed by the Government of Malaysia from time to time (collectively known as "Taxes"). If these fees, charges and/or expenses are subject to any Taxes, such Taxes shall be borne and payable by the Unit Holders and/or the Fund (as the case may be) at the prevailing rate, including any increase or decrease to the rate, in addition to the fees, charges and/or expenses stated herein. Privacy Notice: AmFunds Management Berhad [Company Registration: 198601005272 (154432-A)] issued its Privacy Notice as required by Personal Data Protection Act 2010, which details the use and processing of your personal information by AmFunds Management Berhad. The Privacy Notice can be accessed via www.aminvest.com and is also available at our head office. If you have any queries in relation to the Privacy Notice of AmFunds Management Berhad, please feel free to contact our Customer Service Representative at Tel: +603 2032 2888 OR e-mail: enquiries@aminvest.com.

